The FDAs posture on off-label communication is understandable but incomplete for this scenario
These are Alanine, Glutamic acid, Aspartic acid, and Glycine
The guideline emphasizes intensive lifestyle modification, structured weight-loss programs, obesity pharmacotherapy, and metabolic/bariatric surgery when appropriate
Numerous studies have shown the important role of GLP-1 in protecting against oxidative damage and activating the Nrf2 signaling pathway [22]
The woman enrolled in a small trial at Penn that involved using NAc-focused electrical stimulation to help ease food noise in the brain
And, I expect this cohort to get pretty big, because GLP-1 patients have mismatched expectations (fuelled by social media and AI slop), believing they should be dropping 20lbs a month on these drugs